Enhertu (T-DXd) Superior to Choice of Therapy in HER2-Positive Breast Cancer: DESTINY-Breast02 Trial
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On August 17, 2022, Daiichi Sankyo and AstraZeneca announced positive topline results from the DESTINY-Breast02 Phase 3 clinical trial. This study evaluated the efficacy and safety of Enhertu (Trastuzumab deruxtecan) in patients with HER2-positive unresectable and/or metastatic breast cancer who had been previously treated with T-DM1 (Kadcyla).
Study Design: DESTINY-Breast02 Trial
DESTINY-Breast02 is a global, randomized, multicenter trial designed to confirm the results seen in the earlier DESTINY-Breast01 trial. Patients were randomized to receive either:
- Enhertu (T-DXd).
- Investigator’s Choice of Treatment (either Trastuzumab/Capecitabine or Lapatinib/Capecitabine).
The primary endpoint was progression-free survival (PFS) as assessed by independent central review.
Key Findings
The trial achieved its primary and key secondary endpoints:
- Progression-Free Survival (PFS): Enhertu demonstrated a statistically significant and clinically meaningful improvement in PFS compared to the investigator’s choice of treatment.
- Overall Survival (OS): The trial also confirmed a significant improvement in overall survival for patients treated with Enhertu.
- Safety: The safety profile of Enhertu was consistent with previous clinical trials. While interstitial lung disease (ILD) occurred, its incidence and severity were in line with existing data.
Conclusion
The DESTINY-Breast02 trial reinforces Enhertu’s position as a transformative therapy for HER2-positive metastatic breast cancer patients who have progressed after T-DM1. These results support the continued expansion of access to Enhertu globally, providing a superior treatment option over traditional chemotherapy-based combinations.
Source: Daiichi Sankyo Press Release - DESTINY-Breast02 Results
#BreastCancer #HER2Positive #Enhertu #TDXd #DESTINYBreast02 #CancerResearch #ADC
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4